3-dose of RBD vaccine is sufficient to elicit a long-lasting memory response against SARS-CoV-2 infection
Open Access
- 14 March 2022
- journal article
- letter
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 7 (1) , 1-3
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- The biological and clinical significance of emerging SARS-CoV-2 variantsNature Reviews Genetics, 2021
- COVID-19 vaccines: Keeping pace with SARS-CoV-2 variantsCell, 2021
- Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trialsSignal Transduction and Targeted Therapy, 2021
- Will SARS-CoV-2 variants of concern affect the promise of vaccines?Nature Reviews Immunology, 2021
- Memory B cellsNature Reviews Immunology, 2015
- Lifetime of plasma cells in the bone marrowNature, 1997